<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="14248">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    https://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 13, 2016</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00320749</url>
  </required_header>
  <id_info>
    <org_study_id>OSU-05058</org_study_id>
    <nct_id>NCT00320749</nct_id>
  </id_info>
  <brief_title>Capecitabine, Docetaxel and Gemcitabine in Patients With Advanced Pancreas Cancer</brief_title>
  <official_title>A Dose Escalating (Phase I) Study Looking at the Biomodulation of Capecitabine by Docetaxel and Gemcitabine in Patients With Advanced Pancreas Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Tony Bekaii-Saab</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of Michigan Cancer Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Ohio State University Comprehensive Cancer Center</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary purpose of this study is to define the maximum tolerated dose of combination
      docetaxel, gemcitabine, and capecitabine in patients with pancreatic cancer. Adverse effects
      will be measured in study participants. In addition, researchers will assess data about
      preliminary efficacy in patients with this treatment approach.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Rationale: Single agent gemcitabine is considered standard care for patients with advanced
      pancreatic cancer. However, better treatments offering improved outcomes are needed for
      people with this disease. The combination of docetaxel and capecitabine has shown
      significant and broad clinical activity in a variety of tumors. Laboratory research on the
      combination of capecitabine, docetaxel, and gemcitabine indicates synergistic action against
      tumor cells. The current study will test this combination in patients. The drug
      administration schedule in this study is aimed at maximizing the potential of activation of
      capecitabine by both docetaxel and gemcitabine.

      Treatment: Study participants will be given docetaxel, gemcitabine, and capecitabine. All
      study drugs will be administered through intravenous infusions in three week cycles.
      Docetaxel will be given on days 1 and 8, gemcitabine on days 8 and 15, and capecitabine on
      days 8 through 21. This schedule will be followed by 1 week of rest without administration
      of study drugs. Since the primary goal of this study is to identify the maximum tolerated
      dose of the study drugs in combination, patients who enroll in the beginning of the study
      will receive lower amounts of the study drugs compared to patients who enroll later in the
      study. Several tests and exams will be given throughout the study to closely monitor
      patients.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>December 2005</start_date>
  <completion_date type="Actual">January 2011</completion_date>
  <primary_completion_date type="Actual">October 2008</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <study_design>Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Maximum Tolerated Dose</measure>
    <time_frame>Weekly</time_frame>
    <safety_issue>Yes</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Common Toxicities</measure>
    <time_frame>Weekly</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>The NCI Common Terminology Criteria for Adverse Events version 3.0 was used for adverse event reporting and toxicity grading.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Therapeutic Response</measure>
    <time_frame>Prior to cycle 3 and then every 2 cycles thereafter</time_frame>
    <safety_issue>No</safety_issue>
    <description>Radiological assessment was done every 8 weeks and repsonses were measured according to the RECIST criteria.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">21</enrollment>
  <condition>Pancreatic Cancer</condition>
  <arm_group>
    <arm_group_label>capecitabine, docetaxel, gemcitabine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dose escalation study of mGTX using three dose levels (DL1-3). Patients received docetaxel on days 1 and 8, gemcitabine on days 8 and 15, and capcitabine on days 8 through 21. Gemcitabine fixed dose at 750 mg/m2 over 75 min, capecitabine twice daily and escalated from 500 to 650 mg/m2 at DL2 and docetaxel increased from 30 to 36 mg/m2 at DL3.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Capecitabine</intervention_name>
    <description>Will be give on days 8-21</description>
    <arm_group_label>capecitabine, docetaxel, gemcitabine</arm_group_label>
    <other_name>Xeloda</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Docetaxel</intervention_name>
    <description>Will be given on days 1 and 8,</description>
    <arm_group_label>capecitabine, docetaxel, gemcitabine</arm_group_label>
    <other_name>Taxotere</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Gemcitabine</intervention_name>
    <description>A fixed dose rate will be give on days 8 and 15.</description>
    <arm_group_label>capecitabine, docetaxel, gemcitabine</arm_group_label>
    <other_name>Gemzar</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  adenocarcinoma of the pancreas

          -  no prior chemo except adjuvant

          -  ECOG PS 0-1

          -  peripheral neuropathy &lt;/= Gr. 1

        Exclusion Criteria:

          -  Pregnant/lactating females

          -  Uncontrolled heart disease, diabetes, psychiatric disorder

          -  Therapeutic doses of Warfarin
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Tanios Saab</last_name>
    <role>Principal Investigator</role>
    <affiliation>Ohio State University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Tanios Saab, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Ohio State University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>The University of Michigan Comprehensive Cancer Center</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48109</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ohio State University</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43210</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://cancer.osu.edu</url>
    <description>Jamesline</description>
  </link>
  <results_reference>
    <citation>Hill ME, Li X, Kim S, Campbell A, Culler K, Bloomston M, Zalupski M, Hejna G, Bekaii-Saab T. A phase I study of the biomodulation of capecitabine by docetaxel and gemcitabine (mGTX) in previously untreated patients with metastatic adenocarcinoma of the pancreas. Cancer Chemother Pharmacol. 2011 Mar;67(3):511-7. doi: 10.1007/s00280-010-1348-3. Epub 2010 May 12.</citation>
    <PMID>20461379</PMID>
  </results_reference>
  <verification_date>September 2015</verification_date>
  <lastchanged_date>September 15, 2015</lastchanged_date>
  <firstreceived_date>April 28, 2006</firstreceived_date>
  <firstreceived_results_date>September 15, 2015</firstreceived_results_date>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Ohio State University Comprehensive Cancer Center</investigator_affiliation>
    <investigator_full_name>Tony Bekaii-Saab</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>Advanced Pancreatic Cancer</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Pancreatic Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Capecitabine</mesh_term>
    <mesh_term>Docetaxel</mesh_term>
    <mesh_term>Gemcitabine</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Patients were enrolled into the study between December 2005 and February 2008.</recruitment_details>
      <pre_assignment_details>Patients had histologically or cytologically confirmed metastatic pancreatic adenocarcinoma and measurable disease per RECIST criteria.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Dose Level 1</title>
          <description>Docetaxel IV over 30 min on days 1 and 8 Capecitabine PO in split doses bid on days 8-21 Gemcitabine IV over 75 min on days 8 and 15</description>
        </group>
        <group group_id="P2">
          <title>Dose Level 2</title>
          <description>Docetaxel IV over 30 min on days 1 and 8 Capecitabine PO in split doses bid on days 8-21 Gemcitabine IV over 75 min on days 8 and 15</description>
        </group>
        <group group_id="P3">
          <title>Dose Level 3</title>
          <description>Docetaxel IV over 30 min on days 1 and 8 Capecitabine PO in split doses bid on days 8-21 Gemcitabine IV over 75 min on days 8 and 15</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="8"/>
                <participants group_id="P3" count="10"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="6"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="9"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>18 evaluable</population>
      <group_list>
        <group group_id="B1">
          <title>Capecitabine, Gemcitabine and Docetaxel</title>
          <description>Docetaxel i.v. over 30 min on days 1 and 8; Capecitabine p.o. in split doses bid on days 8-21, Gemcitabine i.v. over 75 min on days 8 and 15.</description>
        </group>
      </group_list>
      <measure_list>
        <measure>
          <title>Number of Participants</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="21"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Age, Customized</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <category_list>
            <category>
              <sub_title>Mean age</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="59" lower_limit="48" upper_limit="72"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>patients</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>Female</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="13"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Male</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="8"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>United States</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="21"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Eastern Cooperative Oncology Group (ECOG)</title>
          <units>patients</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>ECOG 0 (Fully Active)</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="4"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>ECOG 1 (Restricted physical activity)</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="17"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Maximum Tolerated Dose</title>
        <time_frame>Weekly</time_frame>
        <safety_issue>Yes</safety_issue>
        <group_list>
          <group group_id="O1">
            <title>Capecitabine, Docetaxel, Gemcitabine</title>
            <description>Dose escalation study of mGTX using three dose levels (DL1-3). Patients received docetaxel on days 1 and 8, gemcitabine on days 8 and 15, and capcitabine on days 8 through 21. Gemcitabine fixed dose at 750 mg/m2 over 75 min, capecitabine twice daily and escalated from 500 to 650 mg/m2 at DL2 and docetaxel increased from 30 to 36 mg/m2 at DL3.
Capecitabine: Will be give on days 8-21
Docetaxel: Will be given on days 1 and 8,
Gemcitabine: A fixed dose rate will be give on days 8 and 15.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="21"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Maximum Tolerated Dose</title>
            <units>mg/m2</units>
            <param>Number</param>
            <category_list>
              <category>
                <sub_title>docetaxel</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="36"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>gemcitabine</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="750"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>capecitabine</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="625"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Common Toxicities</title>
        <description>The NCI Common Terminology Criteria for Adverse Events version 3.0 was used for adverse event reporting and toxicity grading.</description>
        <time_frame>Weekly</time_frame>
        <safety_issue>Yes</safety_issue>
        <population>grade 3 and grade 4 toxicities according to National Cancer Institute [NCI] Common Toxicity Criteria for Adverse Events [CTCAE], Version 3.0</population>
        <group_list>
          <group group_id="O1">
            <title>Capecitabine, Docetaxel, Gemcitabine</title>
            <description>Dose escalation study of mGTX using three dose levels (DL1-3). Patients received docetaxel on days 1 and 8, gemcitabine on days 8 and 15, and capcitabine on days 8 through 21. Gemcitabine fixed dose at 750 mg/m2 over 75 min, capecitabine twice daily and escalated from 500 to 650 mg/m2 at DL2 and docetaxel increased from 30 to 36 mg/m2 at DL3.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="21"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Common Toxicities</title>
            <description>The NCI Common Terminology Criteria for Adverse Events version 3.0 was used for adverse event reporting and toxicity grading.</description>
            <units>percent of patients</units>
            <param>Number</param>
            <category_list>
              <category>
                <sub_title>leukopenia</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="29"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>neutropenia</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="29"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>fatigue</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="25"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Therapeutic Response</title>
        <description>Radiological assessment was done every 8 weeks and repsonses were measured according to the RECIST criteria.</description>
        <time_frame>Prior to cycle 3 and then every 2 cycles thereafter</time_frame>
        <safety_issue>No</safety_issue>
        <population>3 patients were non-evaluable for response or progression free survival as they withdrew consent after cycle 1 of therapy.</population>
        <group_list>
          <group group_id="O1">
            <title>Capecitabine, Docetaxel, Gemcitabine</title>
            <description>Dose escalation study of mGTX using three dose levels (DL1-3). Patients received docetaxel on days 1 and 8, gemcitabine on days 8 and 15, and capcitabine on days 8 through 21. Gemcitabine fixed dose at 750 mg/m2 over 75 min, capecitabine twice daily and escalated from 500 to 650 mg/m2 at DL2 and docetaxel increased from 30 to 36 mg/m2 at DL3.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="18"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Therapeutic Response</title>
            <description>Radiological assessment was done every 8 weeks and repsonses were measured according to the RECIST criteria.</description>
            <units>percent of patients</units>
            <param>Number</param>
            <category_list>
              <category>
                <sub_title>Partial Response</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="11"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Complete Response</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Stable Disease</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="72"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Capecitabine, Docetaxel, Gemcitabine</title>
          <description>Dose escalation study of mGTX using three dose levels (DL1-3). Patients received docetaxel on days 1 and 8, gemcitabine on days 8 and 15, and capcitabine on days 8 through 21. Gemcitabine fixed dose at 750 mg/m2 over 75 min, capecitabine twice daily and escalated from 500 to 650 mg/m2 at DL2 and docetaxel increased from 30 to 36 mg/m2 at DL3.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="21"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>CTCAE (3.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="21" subjects_at_risk="21"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Leukopenia</sub_title>
                <counts group_id="E1" events="14" subjects_affected="14" subjects_at_risk="21"/>
              </event>
              <event>
                <sub_title>Neutropenia</sub_title>
                <counts group_id="E1" events="11" subjects_affected="11" subjects_at_risk="21"/>
              </event>
              <event>
                <sub_title>Anemia</sub_title>
                <counts group_id="E1" events="10" subjects_affected="10" subjects_at_risk="21"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="16" subjects_affected="16" subjects_at_risk="21"/>
              </event>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" events="16" subjects_affected="16" subjects_at_risk="21"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="8" subjects_affected="8" subjects_at_risk="21"/>
              </event>
              <event>
                <sub_title>Mucositis</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="21"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="18" subjects_affected="18" subjects_at_risk="21"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Transaminitis</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="21"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Thrombocytopenia</sub_title>
                <counts group_id="E1" events="10" subjects_affected="10" subjects_at_risk="21"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Neuropathy</sub_title>
                <counts group_id="E1" events="11" subjects_affected="11" subjects_at_risk="21"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Alopecia</sub_title>
                <counts group_id="E1" events="13" subjects_affected="13" subjects_at_risk="21"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Tanios Bekaii-Saab, M.D.</name_or_title>
      <organization>The Ohio State University Comprehensive Cancer Center</organization>
      <phone>614-293-9863</phone>
      <email>Tanios.Bekaii-Saab@osumc.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>
